



Asensus Surgical Announces Shinmatsudo Central General Hospital in Japan to Initiate Senhance Robotic Surgical System

November 1, 2021

Shinmatsudo Central General Hospital to become 7th Senhance hospital in Japan

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Nov. 1, 2021-- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the Shinmatsudo Central General Hospital in Matsudo, Japan has entered into an agreement to lease and utilize a Senhance® Surgical System.

"We are excited to partner with the Shinmatsudo Central General Hospital, which has extensive experience as a center for excellence in both laparoscopic and surgical robotics," said Anthony Fernando, Asensus Surgical President, and CEO. "We are capitalizing on our recent momentum, securing multiple installations in Japan over the past few months. The addition of Shinmatsudo is a great opportunity to further expand the usage of Senhance in the region."

Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3 mm instruments (the smallest instrument available in the world on a robotic surgical platform). The Senhance Surgical System is powered by the Intelligent Surgical Unit™ (ISU™). The ISU enables machine vision-driven control of the camera for a surgeon by responding to commands and recognizing certain objects and locations in the surgical field, and allows a surgeon to change the visualized field of view using the movement of their instruments.

"We are looking forward to incorporating Senhance into our existing surgical robotics department," said Dr. Ryota Matsuo, M.D., Ph.D., the director of the Shinmatsudo Central General Hospital. "By utilizing this innovative system, we hope to continue providing the highest level of care to our patients while allowing our physicians to leverage the surgical intelligence Senhance provides."

About Shinmatsudo Central General Hospital

Located in the prefecture of Chiba, just outside of Tokyo, Shinmatsudo Central General Hospital is one of 36 hospitals in the IMS group. For nearly 40 years, Shinmatsudo has worked together with the local community to deliver high quality medical care through a comprehensive, cooperative system. The hospital's surgical department offers a wide range of surgical specialties, with a focus on cardiovascular and gastrointestinal surgery, where it employs a variety of surgical solutions including open, laparoscopic, and robotically assisted procedures.

About Asensus Surgical, Inc.

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. For more information, visit www.asensus.com.

Forward-Looking Statements

This press release includes statements relating to the Senhance Surgical System and Shinmatsudo Central General Hospital initiating a program with the Senhance System. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the addition of a Senhance Surgical System at the Shinmatsudo Central General Hospital in Matsudo, Japan will provide a great opportunity to further expand the usage of Senhance in the region. For a discussion of the risks and uncertainties associated with the Company's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 11, 2021 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking

statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20211101005324/en/): <https://www.businesswire.com/news/home/20211101005324/en/>

INVESTOR CONTACT:

Mark Klausner or Mike Vallie, 443-213-0499

invest@asensus.com

or

MEDIA CONTACT:

Kristin Schaeffer, 858-354-8850

CG Life

kschaeffer@cglife.com

Source: Asensus Surgical, Inc.